Search | Clinical Trials Finder

Conditions: Bipolar I Disorder
Interventions: olanzapine, placebo, divalproex; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Essential Tremor
Interventions: 1-Octanol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions: Blood Work; Other
Lead sponsor: Clindove Research LLC; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: NVX-Cov2373; Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 30
States / cities: Long Beach, California • Sacramento, California • DeLand, Florida + 26 more

Conditions: Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions: Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hyperlipidemia
Interventions: Self Monitoring Lipid Analyzer; Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions: Simvastatin, simvastatin plus extended-release niacin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 45 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 15
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 7 more

Conditions: Renal Allograft Recipients
Interventions: Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: LCAT Deficiency
Interventions: Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 40 participants
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity &Amp; Overweight
Interventions: Cardiovascular Exercise, Butyrate; Behavioral · Dietary Supplement
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Prostate Cancer
Interventions: valproic acid, standard of care follow-up; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes
Interventions: Diabetes Medication Choice Decision Aid, Statin Choice Decision Aid, Usual care for lipid therapy medication, Usual care for antihyperglycemic medication; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Albert Lea, Minnesota • Austin, Minnesota • Kasson, Minnesota + 1 more

Conditions: Graft Versus Host Disease
Interventions: stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions: Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 33
States / cities: Irvine, California • Orange, California • Clearwater, Florida + 26 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: omega-3 fatty acid; Dietary Supplement
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 5
States / cities: Wilmington, Delaware • Iowa City, Iowa • Manhasset, New York + 2 more

Conditions: Magnesium Deficiency, Calcium Metabolism Disorders
Interventions: vitamin D3; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: COVID-19
Interventions: Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more

Conditions: Systemic Lupus Erythematosus, Arthritis
Interventions: mycophenolate mofetil, placebo; Drug · Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 14 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Subjects
Interventions: Venlafaxine, Moxifloxacin, Drug - placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mucositis, Graft-versus-host Disease
Interventions: Tac+MTX, TAC + MMF; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Not listed
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Vitamin D3 6000 IU, Vitamin D3 400 IU; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 20 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Fish Oil, High Dose Fish Oil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiovascular Diseases, Hyperlipidemias
Interventions: Lipid Challenge, Glucose Challenge, Mixed Meal Challenge; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

1-Octanol to Treat Essential Tremor

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery

Telephone Based Management of Hyperlipidemia

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study

Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-Responders

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Impact of Decision Aids to Enhance Shared Decision Making for Diabetes

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

How Does Magnesium Status Influence Calcium Homeostasis?

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

The Mixed Meal Challenge Study